NASDAQ:CLLS Cellectis (CLLS) Stock Price, News & Analysis $2.04 -0.01 (-0.49%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$1.94▼$2.0950-Day Range$1.86▼$3.3552-Week Range$0.96▼$3.77Volume16,800 shsAverage Volume49,344 shsMarket Capitalization$113.38 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cellectis alerts: Email Address Cellectis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside292.2% Upside$8.00 Price TargetShort InterestHealthy0.75% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.54) to ($0.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.92 out of 5 starsMedical Sector551st out of 879 stocksBiological Products, Except Diagnostic Industry86th out of 150 stocks 3.5 Analyst's Opinion Consensus RatingCellectis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCellectis has only been the subject of 2 research reports in the past 90 days.Read more about Cellectis' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.75% of the outstanding shares of Cellectis have been sold short.Short Interest Ratio / Days to CoverCellectis has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Cellectis has recently decreased by 1.41%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCellectis does not currently pay a dividend.Dividend GrowthCellectis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLLS. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Cellectis this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CLLS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Cellectis to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cellectis insiders have not sold or bought any company stock.Percentage Held by Insiders16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cellectis' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cellectis are expected to grow in the coming year, from ($0.54) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectis is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectis is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellectis has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cellectis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Cellectis Stock (NASDAQ:CLLS)Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Read More CLLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLLS Stock News HeadlinesJune 28, 2024 | globenewswire.comCellectis Reports Results from Shareholders Meeting Held on June 28, 2024June 20, 2024 | globenewswire.comCellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base EditingJuly 8, 2024 | Porter & Company (Ad)I’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documentary I will provide you with all the details of this one-of-a-kind investment.June 12, 2024 | globenewswire.comCellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature CommunicationsJune 4, 2024 | globenewswire.comCellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic LeukemiaMay 29, 2024 | finance.yahoo.comCellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024May 29, 2024 | globenewswire.comCellectis' Annual Shareholders General Meeting to be Held on June 28, 2024May 28, 2024 | investorplace.comCLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q1 2024July 8, 2024 | Porter & Company (Ad)I’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documentary I will provide you with all the details of this one-of-a-kind investment.May 27, 2024 | globenewswire.comCellectis to Report First Quarter 2024 Financial Results on May 28, 2024May 6, 2024 | globenewswire.comCellectis Announces Completion of the Additional Equity Investment by AstraZenecaMay 2, 2024 | globenewswire.comCellectis Appoints Arthur Stril as Interim Chief Financial OfficerMay 1, 2024 | benzinga.comCellectis Stock (NASDAQ:CLLS), Earnings Estimates, EPS, and RevenueApril 29, 2024 | globenewswire.comCellectis Reports Financial Results for the Fourth Quarter and Full Year 2023April 24, 2024 | seekingalpha.comCLLS Cellectis S.A.April 22, 2024 | globenewswire.comCellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsApril 11, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Decline in Thursday TradingApril 10, 2024 | finance.yahoo.comCellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsSee More Headlines Receive CLLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/28/2024Today7/07/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CLLS CUSIPN/A CIK1627281 Webwww.cellectis.com Phone(318) 169-1600Fax33-1-81-69-16-06Employees231Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+292.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,060,000.00 Net Margins-529.81% Pretax Margin-686.15% Return on Equity-67.41% Return on Assets-20.83% Debt Debt-to-Equity Ratio0.69 Current Ratio1.63 Quick Ratio1.63 Sales & Book Value Annual Sales$9.19 million Price / Sales12.34 Cash FlowN/A Price / Cash FlowN/A Book Value$1.52 per share Price / Book1.34Miscellaneous Outstanding Shares55,580,000Free Float46,463,000Market Cap$113.38 million OptionableOptionable Beta3.10 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Andre Choulika Ph.D. (Age 59)Co-Founder, CEO & Director Comp: $744.02kDr. David j. d. Sourdive Ph.D. (Age 57)Deputy CEO, Executive VP of CMC & Manufacturing and Director Comp: $528.92kDr. Bing C. Wang M.B.A. (Age 47)Ph.D., Chief Financial Officer Valerie CrosPrincipal Financial Officer & Principal Accounting OfficerMr. Jean Charles EpinatChief Technological OfficerDr. Philippe Duchateau Ph.D. (Age 61)Chief Scientific Officer Mr. Stephan Reynier M.Sc. (Age 55)Chief Regulatory & Pharmaceutical Compliance Officer Ms. Marie-Bleuenn Terrier (Age 42)General Counsel & Secretary of the Board of Directors Pascalyne WilsonDirector of CommunicationsMs. Kyung Nam-Wortman (Age 54)Executive VP & Chief Human Resources Officer More ExecutivesKey CompetitorsOcugenNASDAQ:OCGNVoyager TherapeuticsNASDAQ:VYGRTaysha Gene TherapiesNASDAQ:TSHAEditas MedicineNASDAQ:EDITFate TherapeuticsNASDAQ:FATEView All CompetitorsInstitutional OwnershipBaillie Gifford & Co.Bought 10,605 shares on 5/1/2024Ownership: 1.488%Principal Financial Group Inc.Bought 24,906 shares on 4/29/2024Ownership: 0.764%View All Institutional Transactions CLLS Stock Analysis - Frequently Asked Questions How have CLLS shares performed this year? Cellectis' stock was trading at $3.08 at the beginning of 2024. Since then, CLLS shares have decreased by 33.8% and is now trading at $2.04. View the best growth stocks for 2024 here. How were Cellectis' earnings last quarter? Cellectis S.A. (NASDAQ:CLLS) posted its earnings results on Tuesday, May, 28th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. The biotechnology company earned $6.50 million during the quarter. Cellectis had a negative trailing twelve-month return on equity of 67.41% and a negative net margin of 529.81%. What is André Choulika's approval rating as Cellectis' CEO? 13 employees have rated Cellectis Chief Executive Officer André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among the company's employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 39.0% of employees surveyed would recommend working at Cellectis to a friend. When did Cellectis IPO? Cellectis (CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager. How do I buy shares of Cellectis? Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cellectis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD) and CRISPR Therapeutics (CRSP). This page (NASDAQ:CLLS) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.